Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694922 | 1.00 | CCR5 (0.43) | CCR5FFAR1FFAR4P4HTMLTB4R | |
| SCHEMBL6694926 | 1.00 | CCR5 (0.43) | CCR5FFAR1FFAR4P4HTMLTB4R | |
| SCHEMBL5961235 | 0.88 | ME2 (0.43) | SIGMAR1L3MBTL1 | |
| SCHEMBL6700021 | 0.88 | ME2 (0.43) | SIGMAR1L3MBTL1 | |
| SCHEMBL6700517 | 0.84 | FFAR1 (0.44) | CCR5FFAR1FFAR4P4HTMLTB4R | |
| SCHEMBL6700513 | 0.84 | FFAR1 (0.44) | CCR5FFAR1FFAR4P4HTMLTB4R | |
| SCHEMBL6702029 | 0.80 | SCN3A (0.39) | CCR5FFAR1P4HTMACACBACACA | |
| SCHEMBL6702034 | 0.80 | SCN3A (0.39) | CCR5FFAR1P4HTMACACBACACA | |
| SCHEMBL6702030 | 0.80 | SCN3A (0.39) | CCR5FFAR1P4HTMACACBACACA | |
| SCHEMBL6700317 | 0.79 | ME2 (0.35) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | CCR5 573/4885FFAR1 135/4885FFAR4 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.